Nymox Pharm Corp (NYMX) 2.26 $NYMX
Nymox reports 1Q loss
Automated Insights - Mon May 16, 5:11PM CDT
MONTREAL (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a first-quarter loss of $3.3 million, after reporting a profit in the same period a year earlier.
NYMX: 2.26 (-0.12)
Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
GlobeNewswire - Tue Feb 09, 10:07AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.
NYMX: 2.26 (-0.12)
Nymox raises another USD2.1m from equity financing
M2 - Fri Feb 05, 5:02AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) reported on Thursday the completion of USD2.1m private placement equity investment at USD2.00 per share with no warrants.
NYMX: 2.26 (-0.12)
Escherichia Coli Infections - Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/96468r/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Escherichia Coli Infections Overview - Therapeutics Development - Pipeline Products for Escherichia Coli Infections - Overview - Pipeline Products for Escherichia Coli Infections - Comparative Analysis - Escherichia Coli Infections - Therapeutics under Development by Companies - Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes - Escherichia Coli Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Escherichia Coli Infections - Products under Development by Companies - Escherichia Coli Infections - Products under Investigation by Universities/Institutes - Escherichia Coli Infections - Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AstraZeneca Plc - AvidBiotics Corp. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Mucosis B.V. - Navigen Pharmaceuticals, Inc. - Nosopharm SAS - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/96...ichia_coli
TTPH: 3.94 (-0.17), EBS: 42.30 (-1.19), AZN: 27.97 (-0.99), NYMX: 2.26 (-0.12), GSK: 40.93 (-1.13)
Nymox Files Current Financial Statements
GlobeNewswire - Thu Dec 31, 3:45PM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany. The restatement of Q2 2015 was required in order to correct a material accounting error in stock option compensation expense.
NYMX: 2.26 (-0.12)
Nymox Provides Update From Shareholders Annual General Meeting December 16
GlobeNewswire - Thu Dec 17, 8:00AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented:
NYMX: 2.26 (-0.12)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 1.98 (+0.81), NYMX: 2.26 (-0.12)
Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical
ACCESSWIRE - Mon Nov 23, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular Biogenics Ltd (NASDAQ: VBLT), Hutchinson Technology Inc (NASDAQ: HTCH), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and Nymox Pharmaceutical Corp (NASDAQ: NYMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HTCH: 3.79 (+0.24), TNXP: 2.40 (-0.16), NYMX: 2.26 (-0.12), VBLT: 4.90 (+0.10)
Urinary Tract Infections - Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/fx43r6/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Achaogen Inc. - Adenium Biotech ApS - AstraZeneca Plc - ConjuGon, Inc. - Da Volterra - DexTech Medical AB - Enteris BioPharma, Inc. - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - Merck & Co., Inc. - MerLion Pharmaceuticals Pte Ltd - Nabriva Therapeutics AG - Nippon Shinyaku Co., Ltd. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Paratek Pharmaceuticals, Inc. - Pivot Pharmaceuticals Inc - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Syntiron LLC - The Medicines Company - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/fx...nary_tract
MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27), NYMX: 2.26 (-0.12), PRTK: 16.01 (-0.05), GSK: 40.93 (-1.13), NBRV: 7.20 (+0.06)
Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
GlobeNewswire - Thu Oct 29, 9:31AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company's trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.
NYMX: 2.26 (-0.12)
Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
GlobeNewswire - Thu Oct 08, 10:00AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported this quarter, after the 18 month data has been analyzed. Patients in the prostate cancer study have been followed for up to 39 months after treatment.
NYMX: 2.26 (-0.12)
Technical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and Tesla Motors
PR Newswire - Tue Sep 22, 7:12AM CDT
ACI Association has initiated research coverage on the following equities: Bill Barrett Corp (NYSE: BBG), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), GoPro Inc (NASDAQ: GPRO), Mondelez International Inc (NASDAQ: MDLZ), and Tesla Motors Inc (NASDAQ: TSLA). On Monday, September 21, 2015, Nasdaq ended at 4,828.95 up 0.04%, DOW advanced 0.77%, to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
TSLA: 218.79 (-10.57), GPRO: 10.26 (-0.64), MDLZ: 45.02 (-0.20), BBG: 7.74 (-0.89), NYMX: 2.26 (-0.12)
Nymox Announces Change of Company's Domicile and Head Office
GlobeNewswire - Tue Aug 04, 10:45AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.
NYMX: 2.26 (-0.12)
Escherichia Coli Infections - Pipeline Review, H1 2015: Analysis of 35 Companies & 62 Drug Profiles
M2 - Fri Jul 31, 8:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xjrsw/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - Genentech, Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - Mucosis B.V. - Nabriva Therapeutics AG - Navigen Pharmaceuticals, Inc. - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/9x...ichia_coli
EBS: 42.30 (-1.19), NYMX: 2.26 (-0.12), GSK: 40.93 (-1.13), NBRV: 7.20 (+0.06)
Nymox elects James G. Robinson to board
M2 - Fri Jul 31, 4:25AM CDT
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday that it has appointed James G. Robinson to its board of directors.
NYMX: 2.26 (-0.12)
Nymox Announces Appointment of James G. Robinson to Board of Directors
GlobeNewswire - Thu Jul 30, 10:15AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.
NYMX: 2.26 (-0.12)
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - Tue Jul 28, 11:00AM CDT
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 2.26 (-0.12)
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 2.26 (-0.12)
Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 2.26 (-0.12)
Nymox Announces Appointment of Erik Danielsen as CFO
GlobeNewswire - Mon Jul 13, 12:15PM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.
NYMX: 2.26 (-0.12)
Nymox reports 1Q loss
Automated Insights - Mon May 16, 5:11PM CDT
MONTREAL (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a first-quarter loss of $3.3 million, after reporting a profit in the same period a year earlier.
NYMX: 2.26 (-0.12)
Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
GlobeNewswire - Tue Feb 09, 10:07AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.
NYMX: 2.26 (-0.12)
Nymox raises another USD2.1m from equity financing
M2 - Fri Feb 05, 5:02AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) reported on Thursday the completion of USD2.1m private placement equity investment at USD2.00 per share with no warrants.
NYMX: 2.26 (-0.12)
Escherichia Coli Infections - Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/96468r/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Escherichia Coli Infections Overview - Therapeutics Development - Pipeline Products for Escherichia Coli Infections - Overview - Pipeline Products for Escherichia Coli Infections - Comparative Analysis - Escherichia Coli Infections - Therapeutics under Development by Companies - Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes - Escherichia Coli Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Escherichia Coli Infections - Products under Development by Companies - Escherichia Coli Infections - Products under Investigation by Universities/Institutes - Escherichia Coli Infections - Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AstraZeneca Plc - AvidBiotics Corp. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Mucosis B.V. - Navigen Pharmaceuticals, Inc. - Nosopharm SAS - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/96...ichia_coli
TTPH: 3.94 (-0.17), EBS: 42.30 (-1.19), AZN: 27.97 (-0.99), NYMX: 2.26 (-0.12), GSK: 40.93 (-1.13)
Nymox Files Current Financial Statements
GlobeNewswire - Thu Dec 31, 3:45PM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany. The restatement of Q2 2015 was required in order to correct a material accounting error in stock option compensation expense.
NYMX: 2.26 (-0.12)
Nymox Provides Update From Shareholders Annual General Meeting December 16
GlobeNewswire - Thu Dec 17, 8:00AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented:
NYMX: 2.26 (-0.12)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 1.98 (+0.81), NYMX: 2.26 (-0.12)
Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical
ACCESSWIRE - Mon Nov 23, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular Biogenics Ltd (NASDAQ: VBLT), Hutchinson Technology Inc (NASDAQ: HTCH), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and Nymox Pharmaceutical Corp (NASDAQ: NYMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HTCH: 3.79 (+0.24), TNXP: 2.40 (-0.16), NYMX: 2.26 (-0.12), VBLT: 4.90 (+0.10)
Urinary Tract Infections - Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/fx43r6/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Achaogen Inc. - Adenium Biotech ApS - AstraZeneca Plc - ConjuGon, Inc. - Da Volterra - DexTech Medical AB - Enteris BioPharma, Inc. - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - Merck & Co., Inc. - MerLion Pharmaceuticals Pte Ltd - Nabriva Therapeutics AG - Nippon Shinyaku Co., Ltd. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Paratek Pharmaceuticals, Inc. - Pivot Pharmaceuticals Inc - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Syntiron LLC - The Medicines Company - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/fx...nary_tract
MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AKAO: 3.86 (-0.27), NYMX: 2.26 (-0.12), PRTK: 16.01 (-0.05), GSK: 40.93 (-1.13), NBRV: 7.20 (+0.06)
Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
GlobeNewswire - Thu Oct 29, 9:31AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company's trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.
NYMX: 2.26 (-0.12)
Nymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
GlobeNewswire - Thu Oct 08, 10:00AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported this quarter, after the 18 month data has been analyzed. Patients in the prostate cancer study have been followed for up to 39 months after treatment.
NYMX: 2.26 (-0.12)
Technical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and Tesla Motors
PR Newswire - Tue Sep 22, 7:12AM CDT
ACI Association has initiated research coverage on the following equities: Bill Barrett Corp (NYSE: BBG), Nymox Pharmaceutical Corporation (NASDAQ: NYMX), GoPro Inc (NASDAQ: GPRO), Mondelez International Inc (NASDAQ: MDLZ), and Tesla Motors Inc (NASDAQ: TSLA). On Monday, September 21, 2015, Nasdaq ended at 4,828.95 up 0.04%, DOW advanced 0.77%, to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
TSLA: 218.79 (-10.57), GPRO: 10.26 (-0.64), MDLZ: 45.02 (-0.20), BBG: 7.74 (-0.89), NYMX: 2.26 (-0.12)
Nymox Announces Change of Company's Domicile and Head Office
GlobeNewswire - Tue Aug 04, 10:45AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.
NYMX: 2.26 (-0.12)
Escherichia Coli Infections - Pipeline Review, H1 2015: Analysis of 35 Companies & 62 Drug Profiles
M2 - Fri Jul 31, 8:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xjrsw/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - Genentech, Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - Mucosis B.V. - Nabriva Therapeutics AG - Navigen Pharmaceuticals, Inc. - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/9x...ichia_coli
EBS: 42.30 (-1.19), NYMX: 2.26 (-0.12), GSK: 40.93 (-1.13), NBRV: 7.20 (+0.06)
Nymox elects James G. Robinson to board
M2 - Fri Jul 31, 4:25AM CDT
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday that it has appointed James G. Robinson to its board of directors.
NYMX: 2.26 (-0.12)
Nymox Announces Appointment of James G. Robinson to Board of Directors
GlobeNewswire - Thu Jul 30, 10:15AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.
NYMX: 2.26 (-0.12)
Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online
GlobeNewswire - Tue Jul 28, 11:00AM CDT
Nymox's (NASDAQ:NYMX) July 27 webcast of news and discussion by experts of the Company's new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_inves...r_vod.html. The link is also available at the Company's website.
NYMX: 2.26 (-0.12)
Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File for Regulatory Approvals for Fexapotide Triflutate (NX-1207).
GlobeNewswire - Mon Jul 27, 8:30AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
NYMX: 2.26 (-0.12)
Nymox Appoints Cutler & Co. as Auditor
GlobeNewswire - Thu Jul 16, 5:03PM CDT
On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company's new independent registered public accounting firm to replace KPMG LLP. Prior to the date of Cutler's engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.
NYMX: 2.26 (-0.12)
Nymox Announces Appointment of Erik Danielsen as CFO
GlobeNewswire - Mon Jul 13, 12:15PM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company. Mr. Danielsen is a highly experienced financial analyst with special expertise in emerging health care companies, and with extensive international business knowledge.
NYMX: 2.26 (-0.12)
